Literature DB >> 17163912

Antidepressant pharmacotherapy: considerations for the pain clinician.

Kenneth C Jackson1, Erin L St Onge.   

Abstract

Antidepressant pharmacotherapy presents many challenges to clinicians dealing with patients suffering from chronic pain. Co-existent depression and pain continues to present clinicians with a plethora of difficult treatment selections. Treated in isolation, each of these disease states can prove difficult to treat. Collectively, depression and pain often present significantly more difficult challenges to the clinician. Antidepressants may be used as a primary treatment modality for depression in a patient dealing with chronic pain. At other times these agents may be used to treat certain specific chronic pain syndromes, possibly in the face of concomitant depression. Clinicians should be aware of the many peculiarities associated with this broad class of medications. Included in this review are considerations for drug selection, dose escalation, and common drug related problems (eg, adverse drug reactions). In addition, attention is paid to the appropriate selection of an agent for use in either the primary management of pain or depression.

Entities:  

Year:  2003        PMID: 17163912     DOI: 10.1046/j.1533-2500.2003.03020.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  14 in total

1.  Prevalence and treatment of depression in children and adolescents with sickle cell disease: a retrospective cohort study.

Authors:  Jeanette M Jerrell; Avnish Tripathi; Roger S McIntyre
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  A combined effect of dextromethorphan and melatonin on neuropathic pain behavior in rats.

Authors:  Shuxing Wang; Lin Zhang; Grewo Lim; Backil Sung; Yinghong Tian; Chiu-Wen Chou; Hayley Hernstadt; Gabriel Rusanescu; Yuxin Ma; Jianren Mao
Journal:  Brain Res       Date:  2009-07-09       Impact factor: 3.252

3.  Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses.

Authors:  Ying Xu; Lu Zhang; Tuo Shao; Lina Ruan; Lin Wang; Jiao Sun; Jianxin Li; Xinbo Zhu; James M O'Donnell; Jianchun Pan
Journal:  Metab Brain Dis       Date:  2013-04-14       Impact factor: 3.584

4.  Exacerbated mechanical allodynia in rats with depression-like behavior.

Authors:  Qing Zeng; Shuxing Wang; Grewo Lim; Liling Yang; Ji Mao; Backil Sung; Yang Chang; Jeong-Ae Lim; Gongshe Guo; Jianren Mao
Journal:  Brain Res       Date:  2008-01-26       Impact factor: 3.252

5.  Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.

Authors:  Eylem Sahin Cankurtaran; Elvan Ozalp; Haldun Soygur; Derya Iren Akbiyik; Levent Turhan; Necati Alkis
Journal:  Support Care Cancer       Date:  2008-02-26       Impact factor: 3.603

6.  Skimmetin/osthole mitigates pain-depression dyad via inhibiting inflammatory and oxidative stress-mediated neurotransmitter dysregulation.

Authors:  Lovedeep Singh; Anudeep Kaur; Saweta Garg; Rajbir Bhatti
Journal:  Metab Brain Dis       Date:  2020-09-01       Impact factor: 3.584

7.  Pain, pain, go away: antidepressants and pain management.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2008-12

8.  The Effect of Acute Intra Locus Coeruleus (LC) Microinfusion of Bupropion on Formalin-Induced Pain Behavior in Rat.

Authors:  Marzieh Jahanbani; Sima Nasri; Firouz Ghaderi Pakdel; Ulker Cankurt; Parviz Shahabi; Sanaz Amirabadi; Somayyeh Naderi; Mostafa Ashrafi Osalou
Journal:  Basic Clin Neurosci       Date:  2014

9.  Acute systemic infusion of bupropion decrease formalin induced pain behavior in rat.

Authors:  Somayyeh Naderi; Firouz Ghaderi Pakdel; Mostafa Ashrafi Osalou; Ulker Cankurt
Journal:  Korean J Pain       Date:  2014-03-28

Review 10.  An overview of the management of post-vasectomy pain syndrome.

Authors:  Wei Phin Tan; Laurence A Levine
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.